Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001238 · ClinicalTrials.gov registry record
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
A clinical trial of Renal Cell Carcinoma and Kidney Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT00001238 is a study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 5,000 participants, above the 202-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (2375% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00001238, a study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 1990-12-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001238
The ClinicalTrials.gov registry entry for NCT00001238 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (2375% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT00001238 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001238 about?
NCT00001238 is a clinical study titled "Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders". We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant dis...
What is the current status of trial NCT00001238?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 1990-12-05.
What conditions does trial NCT00001238 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Urologic Malignant Disorders, Familial Renal Cancer (FRC), Clear Cell Renal Cancer.
Who is sponsoring clinical trial NCT00001238?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001238 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.